Navigation Links
Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Date:9/26/2011

GREENWOOD VILLAGE, Colo., Sept. 26, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced positive results from a 12-week open label extension study that was performed at the conclusion of the Phase III trials for Zertane™ in patients with premature ejaculation.  No treatment-related serious adverse events and very few adverse events were recorded during the open-label extension period, when all subjects received active treatment, even though the mean extent of exposure (approximately 0.26 to 0.31 tablets per day) appeared to increase modestly compared to the double-blind treatment period (approximately 0.24 to 0.26 tablets per day). The average use by patients during this 12 week period remained less than 3 pills per week.  Six subjects experienced an adverse event (5.9%) with only one treatment-related adverse event (anxiety/erectile dysfunction), demonstrating that even the higher dose of Zertane™ proves to be safe with a longer follow-up. There were no reports of dependency or tolerability issues.

"These findings of safety during an extended period of time beyond our Phase III clinical trial in men with premature ejaculation help diminish any potential concerns about safety or dependency with the use of the active ingredient of Zertane™," said Don Wingerter, Ampio CEO.

About the Study

The two Phase III trials for Zertane™ were conducted in 62 sites and 11 countries in Europe (results recently published in European Urology). In the open label extension trial, all subjects participating in this study (n=101) received the higher dose of Zertane™ (89 mg), and were evaluated at 3-week intervals for a total of four visits. Safety data col
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
2. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
3. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
4. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
5. Ampio Pharmaceuticals Set to Join Russell 3000 Index
6. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
7. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
8. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
9. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
...  BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... license and development agreement with Endo Pharmaceuticals (Nasdaq: ... to develop and commercialize BEMA Buprenorphine for the ... patented and proven BioErodible MucoAdhesive (BEMA) technology to ...
... conjunction with its fourth quarter 2011 earnings release (expected to ... Inc. (NYSE: CVD ) is pleased to invite ... will be broadcast live over the Internet on Thursday, January ... , What:       , , , Covance Fourth Quarter 2011 Earnings ...
Cached Medicine Technology:BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 2BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 3BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 4BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 5
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... pain today are much less likely to die, or to experience ... according to a new international study. ,It's the first ... rate of heart failure and death over such a short time ... change occurred at the same time that hospitals increased their use ...
... failed to improve symptoms of moderate to severe chronic ... multi-center trial. ,The results of the ... the first issue of the May American Journal of ... Thoracic Society. ,According to an editorial commenting ...
... Junior doctors who do not get training posts through ... further misery because the government is stalling on ... warns. ,Latest figures show that 34,250 doctors ... The government has so far given no commitment that ...
... cream for enhancing sexual desire in female cancer survivors did ... Mayo clinic has shown. ,A low sex ... to a previous study which pointed a link between androgen ... levels, this new study was conducted on 150 post menopausal ...
... is now infusing roasted sunflower seeds with caffeine ... provide players and other people the extra energy needed to ... been under development since an year, are grown in North ... Products) plant at Willow Lake where caffeine, taurine, lysine and ...
... there is no hard and fast rule as to how a ... more than glad to endorse that view as standard positions ... motherly feelings to override. , Take the case of ... when her daughter Deborah was born. ,As manager of ...
Cached Medicine News:Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3
... solid made, manual plate washer for ... dispense and aspirate function ensure proper ... a stand and all necessary tubings. ... as well as any bottles for ...
... MP-1200 is a compact and simple ... internal micropumps enable the system both ... all types of microtiter well. MW-1200 ... in rows of 8 wells or ...
High precision microplate washer for immuno and adherent cell assays. For use with all strip types and full microplate in 96- and 384-well format in both portrait and landscape orientations....
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use....
Medicine Products: